Citations

Showing 10 of 108081 citations.

Current Understanding and Management of Splenic Steal Syndrome after Liver Transplant: A Systematic Review
Tsui, Brian , Li, Chaolun , Kapoor, Baljendra , Moon, Eunice , Quintini, Cristiano , Wang, Weiping

Mayo Clinic

Digestive Disease Interventions | June 8, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0037-1603724 Get It

Added Value of Covered Stents in Transjugular Intrahepatic Portosystemic Shunt: A Large Single-Center Experience
Wang, Weiping , Shah, Chintan , Sands, Mark, Bullen, Jennifer , Bayona, Pilar, Carey, William, Kapoor, Baljendra , Gupta, Amar C. , Remer, Erick M.

Mayo Clinic

Digestive Disease Interventions | June 8, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0037-1603696 Get It

Lymphaticovenous Bypass: Adaptations and Lessons Learned
Baltzer, Heather L. , Winocour, Sebastian, Harless, Christin A., Saint‐Cyr, Michel, Harless, Christin

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | June 8, 2017 | Volume: 5 | Issue: 6 | Pages: e1328

10.1097/gox.0000000000001328 | PMID 28740763 Get It

Summary: Advances in microsurgical instruments and techniques have allowed for introduction of lymphaticovenous anastomosis as a potential surgical treatment for patients with upper and lower extremity lymphedema. This article reviews the approach to lymphaticovenous anastomosis patient selection and technical modifications that improve the ease and efficiency of the procedure.
Mediastinal seminoma presenting with superior vena cava syndrome
Wanous, Amanda A., McPhail, Ian R., Quevedo, J. Fernando , Sandhu, Nicole P. , Wanous, Amanda

Mayo Clinic

BMJ Case Reports | June 8, 2017 | Volume: 2017 | Issue: No issue available | Pages: bcr-2016-218282

10.1136/bcr-2016-218282 | PMID 28596199 Get It

We present a rare cause of superior vena cava syndrome (SVC) in a previously healthy male aged 31 years. Malignancy was suspected due to unintentional weight loss and childhood exposure to radioactive fallout from a nuclear facility accident. A very large anterior mediastinal mass was identified and demonstrated to be an extragonadal seminoma. Extragonadal germ cell tumours are rare tumours with a high potential for cardiovascular, pulmonary and vascular sequelae. Studies have documented an increased risk of developing seminoma in patients with radioactive exposure. Chemotherapy was initiated, during which the patient experienced progressive and new symptoms, found to be due to extensive thromboembolic disease, which responded well to anticoagulation. Seventy-two months after completing chemotherapy, without need for surgical management, he remains free of the disease.
Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study
Bari, Berardino De , Stish, Bradley J. , Ball, Mark W. , Habboush, Yacob , Sargos, Paul , Krengli, Marco , Bossi, Alberto , Stabile, Armando , Sole, Claudio V. , Lestrade, L., Smeenk, Robert Jan , Jereczek‐Fossa, Barbara Alicja , Créhange, G. , Alongi, Filippo , Özsahin, Mahmut, De Bari, Berardino , Stish, Bradley, Zilli, Thomas , Zaorsky, Nicholas G. , Stabile, Armando

Mayo Clinic

The Prostate | June 8, 2017 | Volume: 77 | Issue: 10 | Pages: 1160-1166

10.1002/pros.23375 | PMID 28594087 Get It

IntroductionAdult prostatic sarcoma (PS) is a rare disease. While surgery is considered the standard approach, the role of other therapies is not completely established. We report results of the largest multicentric contemporary cohort of PS patients.Materials and MethodsThis study included 61 adult PS patients treated in 16 American and European Institutions. Median age was 64.4 years (range: 22‐87). Curative surgery was delivered in 48 patients (prostatectomy = 26, cystoprostatectomy = 22), usually with lymphadenectomy (n = 40). Curative radiotherapy (RT) was delivered in 32 patients, as radical (n = 5), neoadjuvant (n = 10), or postoperative treatment (n = 17). Eighteen patients received chemotherapy. None of the patients received hormonal therapy.ResultsMedian follow‐up was 72 months (95%CI: 55‐not reached). Five‐year local control (LC), overall survival (OS), cancer‐specific survival, disease‐free survival, and metastases‐free rates were 47%, 53%, 56%, 35%, and 35%, respectively. Notably, curative RT (neoadjuvant, adjuvant, or definitive) was associated with improved 5‐year LC (55% vs. 31%, P = 0.02) and OS (59% vs. 46%, P = 0.1). Surgically treated patients presenting with a cT3‐4 tumor (n = 31), who received RT (n = 24), had a significantly improved 5‐year LC (68% vs, 33%, P = 0.004) and OS (65% vs. 21%, P < 0.001) rates compared to patients not receiving RT. cT4 patients demonstrated a significantly lower 5‐year OS (43% vs. 61%, P = 0.006) and LC (29% vs. 69%, P < 0.001) rates. Histologic subtype was not associated with LC and OS, but patients with prostatic stromal sarcoma, rhabdomyosarcoma, or sarcomatoid carcinoma had worse 5‐year LC compared to other types (47% vs. 55%) and OS (49% vs. 58%).ConclusionAdult PS has a poor prognosis. Locally advanced tumors have poor LC and OS rates. Curative RT should be considered part of the multidisciplinary approach to PS.
Coronary flow reserve in patients with aortic stenosis and nonobstructed coronary arteries
Banović, Marko , Vujisić-Tešić, Bosiljka, Kujacic, Vuk, Callahan, Mark J., Nedeljković, Ivana , Trifunovic, Danijela D., Aleksandric, S , Petrovic, Milan, Obradović, Slobodan , Ostojić, Miodrag

Mayo Clinic

Acta Cardiologica | June 8, 2017 | Volume: 66 | Issue: 6 | Pages: 743-749

10.1080/ac.66.6.2136958 | PMID 22299385 Get It

Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer
Muchtar, Eli , Kumar, Shaji , Magen, Hila , Gertz, Morie A. , Kumar, Shaji K , Gertz, Morie A , Muchtar, E

Mayo Clinic

Leukemia & Lymphoma | June 8, 2017 | Volume: 59 | Issue: 2 | Pages: 288-299

10.1080/10428194.2017.1334124 | PMID 28592156 Get It

Performance characterization of a 3D liquid scintillation detector for discrete spot scanning proton beam systems
Darne, Chinmay , Alsanea, Fahed , Robertson, Daniel , Sahoo, Narayan , Beddar, Sam , Robertson, Daniel G

Mayo Clinic

Physics in Medicine & Biology | June 8, 2017 | Volume: 62 | Issue: 14 | Pages: 5652-5667

10.1088/1361-6560/aa780b | PMID 28593931 Get It

Abstract Existing systems for proton beam dosimetry are limited in their ability to provide a complete, accurate, and detailed account of volumetric dose distribution. In this work, we describe the design and development of a portable, fast, and reusable liquid scintillator-based three-dimensional (3D) optical detection system for use in proton therapy. Our long-term goal is to use this system clinically for beam characterization, dosimetry, and quality assurance studies of discrete spot scanning proton beam systems. The system used a 20 × 20 × 20 cm 3 liquid scintillator volume. Three mutually orthogonal cameras surrounding this volume captured scintillation photons emitted in response to the proton beams. The cameras exhibited a mean spatial resolution of 0.21 mm over the complete detection volume and a temporal resolution of 11 ms. The system is shown to be capable of capturing all 94 beam energies delivered by a synchrotron and performing rapid beam range measurements with a mean accuracy of 0.073 ± 0.030 mm over all energies. The range measurement uncertainty for doses less than 1 cGy was found to be ±0.355 mm, indicating high precision for low dose detection. Finally, we demonstrated that using multiple cameras allowed for the precise locations of the delivered beams to be tracked in 3D. We conclude that this detector is capable of real-time and accurate tracking of dynamic spot beam deliveries in 3D. The high-resolution light profiles it generates will be useful for future 3D construction of dose maps.
Use of copeptin for rapid rule-out of acute myocardial infarction
Mueller, Christian, Möckel, Martin , Huber, Kurt , Mair, Johannes , Thygesen, Kristian , Jaffe, Allan S. , Giannitsis, Evangelos , Plebani, Mario , Jaffe, Allan S. , Lindahl, Bertil , Huber, Kurt , Mockel, Martin

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | June 8, 2017 | Volume: 7 | Issue: 6 | Pages: 570-576

10.1177/2048872617710791 | PMID 28593800 Get It

Copeptin is currently understood as a quantitative marker of endogenous stress. It rises rapidly in multiple acute disorders including acute myocardial infarction. As a single variable, it has only modest diagnostic accuracy for acute myocardial infarction. However, the use of copeptin within a dual-marker strategy together with conventional cardiac troponin increases the diagnostic accuracy and particularly the negative predictive value of cardiac troponin alone for acute myocardial infarction. The rapid rule-out of acute myocardial infarction is the only application in acute cardiac care mature enough to merit consideration for routine clinical care. However, the dual-marker approach seems to provide only very small incremental value when used in combination with sensitive or high-sensitivity cardiac troponin assays. This review aims to update and educate regarding the potential and the procedural details, as well as the caveats and challenges of using copeptin in clinical practice.
Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia
Larsen, Carolyn , Villarraga, Hector R. , Begna, Kebede H. , Litzow, Mark R. , Al‐Kali, Aref , Herrmann, Joerg , Larsen, Carolyn M

Mayo Clinic

Leukemia & Lymphoma | June 8, 2017 | Volume: 59 | Issue: 1 | Pages: 229-232

10.1080/10428194.2017.1323268 | PMID 28592197 Get It